Dishman Carbogen Amcis: Q4FY26 & FY26 Results & Investor Presentation
Dishman Carbogen Amcis reported Q4FY26 Net Revenue of ₹8,514 million (up 18.9% YoY) and FY26 Net Revenue of ₹29,319 million (up 8.1% YoY). EBITDA margins improved to 19.3% in FY26 from 17.3% in FY25. Net debt reduced to CHF 146.80 million. The company is focusing on oncology, with 12 molecules in Phase III.
The announcement includes detailed financial results for the quarter and full year, along with strategic information about growth areas and debt reduction, which are material for investors.
The company reported revenue growth in both Q4FY26 and FY26, along with an improvement in EBITDA margins for the full fiscal year. There was also a reduction in net debt, indicating positive financial performance and management.
Dishman Carbogen Amcis Limited has released its audited financial results for the quarter and year ended March 31, 2026, along with an investor presentation. The company reported a Net Revenue of ₹8,514 million for Q4FY26, an increase of 18.9% compared to ₹7,163 million in Q4FY25. For the full fiscal year FY26, Net Revenue stood at ₹29,319 million, up 8.1% from ₹27,115 million in FY25. The CDMO segment revenue saw a significant increase of 21.3% in Q4FY26 year-on-year, driven by higher commercial revenue, and a 6.5% YoY increase for FY26 due to higher development revenue from late-phase III molecules. The Marketable Molecules (MM) segment revenue grew by 9.3% in Q4FY26 and 17.2% in FY26, primarily due to increased supplies of Vitamin D analogues. EBITDA margins for Q4FY26 were 19.1%, a decrease from 21.3% in Q4FY25, mainly due to a reduction in CDMO segment margins. However, EBITDA margins for FY26 improved to 19.3% from 17.3% in FY25, attributed to increased CDMO development revenue and improved MM segment margins driven by Vitamin D analogue sales and cost reductions. The company also noted a capital expenditure of CHF 22.4 million during the year and a reduction in net debt (excluding lease liabilities) to CHF 146.80 million as of March 31, 2026, from CHF 157.6 million as of March 31, 2025. The presentation highlights the company's integrated CDMO capabilities, global presence, and focus on complex modalities like ADC & Bioconjugation, High Potent API, Chromatography, and Continuous Flow Chemistry. Oncology is identified as a key growth area, with the company having 12 molecules in Phase III development, many of which are in the oncology segment.
What to do with a filing like this
Dishman Carbogen Amcis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dishman Carbogen Amcis Limited. Read the original for the full detail.